Skip to main content

Advertisement

Peer Review reports

From: Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

Original Submission
19 Aug 2017 Submitted Original manuscript
1 Oct 2017 Reviewed Reviewer Report - Giovanni Grignani
16 Feb 2018 Reviewed Reviewer Report - Tetsuhiko Asao
17 Apr 2018 Author responded Author comments - Tetsu Hayashida
Resubmission - Version 2
17 Apr 2018 Submitted Manuscript version 2
11 May 2018 Reviewed Reviewer Report - Tetsuhiko Asao
31 May 2018 Reviewed Reviewer Report - Giovanni Grignani
8 Jun 2018 Author responded Author comments - Tetsu Hayashida
Resubmission - Version 3
8 Jun 2018 Submitted Manuscript version 3
17 Jun 2018 Author responded Author comments - Tetsu Hayashida
Resubmission - Version 4
17 Jun 2018 Submitted Manuscript version 4
21 Jun 2018 Author responded Author comments - Tetsu Hayashida
Resubmission - Version 5
21 Jun 2018 Submitted Manuscript version 5
Publishing
22 Jun 2018 Editorially accepted
28 Jun 2018 Article published 10.1186/s12885-018-4628-7

You can find further information about peer review here.

Back to article page